Mercer Global Advisors
AMLX icon

Mercer Global Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Mercer Global Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.9K Buy
+2,888
New +$44.7K ﹤0.01% 4279

Other funds holding AMLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JTL
Jupiter Topco LLC New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Mercer Global Advisors's AMLX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 2,888 shares worth $51.9K. The stake represents ﹤0.01% of the portfolio and ranks #4279 among its holdings.

182 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Mercer Global Advisors held 2,888 shares of Amylyx Pharmaceuticals worth $51.9K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Mercer Global Advisors position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4279 holding.
  • 182 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.